Literature DB >> 28418072

MYB-GATA1 fusion promotes basophilic leukaemia: involvement of interleukin-33 and nerve growth factor receptors.

Stéphane Ducassou1,2, Valérie Prouzet-Mauléon1, Marie-Céline Deau1, Philippe Brunet de la Grange3, Bruno Cardinaud1,4, Hayssam Soueidan1, Cathy Quelen5, Pierre Brousset5, Jean-Max Pasquet6, François Moreau-Gaudry6, Michel Arock7, François-Xavier Mahon1,8, Eric Lippert6,9.   

Abstract

Acute basophilic leukaemia (ABL) is a rare subtype of acute myeloblastic leukaemia. We previously described a recurrent t(X;6)(p11;q23) translocation generating an MYB-GATA1 fusion gene in male infants with ABL. To better understand its role, the chimeric MYB-GATA1 transcription factor was expressed in CD34-positive haematopoietic progenitors, which were transplanted into immunodeficient mice. Cells expressing MYB-GATA1 showed increased expression of markers of immaturity (CD34), of granulocytic lineage (CD33 and CD117), and of basophilic differentiation (CD203c and FcϵRI). UT-7 cells also showed basophilic differentiation after MYB-GATA1 transfection. A transcriptomic study identified nine genes deregulated by both MYB-GATA1 and basophilic differentiation. Induction of three of these genes (CCL23, IL1RL1, and NTRK1) was confirmed in MYB-GATA1-expressing CD34-positive cells by reverse transcription quantitative polymerase chain reaction. Interleukin (IL)-33 and nerve growth factor (NGF), the ligands of IL-1 receptor-like 1 (IL1RL1) and neurotrophic receptor tyrosine kinase 1 (NTRK1), respectively, enhanced the basophilic differentiation of MYB-GATA1-expressing UT-7 cells, thus demonstrating the importance of this pathway in the basophilic differentiation of leukaemic cells and CD34-positive primary cells. Finally, gene reporter assays confirmed that MYB and MYB-GATA1 directly activated NTRK1 and IL1RL1 transcription, leading to basophilic skewing of the blasts. MYB-GATA1 is more efficient than MYB, because of better stability. Our results highlight the role of IL-33 and NGF receptors in the basophilic differentiation of normal and leukaemic cells.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  IL1RL1; MYB-GATA1; NTRK1; basophils; leukaemia

Mesh:

Substances:

Year:  2017        PMID: 28418072     DOI: 10.1002/path.4908

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

Review 1.  Acute Basophilic Leukemia: Recent Molecular and Diagnostic Update.

Authors:  Gyanendra Singh
Journal:  Cureus       Date:  2022-06-17

2.  Acute basophilic leukemia associated with the t(16;21)(p11;q22)/FUS-ERG fusion gene.

Authors:  Yusuke Toda; Yuya Nagai; Daiki Shimomura; Chiyuki Kishimori; Katsuyo Tsuda; Katsuhiro Fukutsuka; Masahiko Hayashida; Hitoshi Ohno
Journal:  Clin Case Rep       Date:  2017-10-11

3.  Predictors of early-onset post-ischemic stroke depression: a cross-sectional study.

Authors:  Guilin Meng; Xiaoye Ma; Lei Li; Yan Tan; Xiaohui Liu; Xueyuan Liu; Yanxin Zhao
Journal:  BMC Neurol       Date:  2017-11-17       Impact factor: 2.474

Review 4.  Interleukin-33 in Malignancies: Friends or Foes?

Authors:  Jia-Xin Shen; Jing Liu; Guo-Jun Zhang
Journal:  Front Immunol       Date:  2018-12-20       Impact factor: 7.561

Review 5.  MYB oncoproteins: emerging players and potential therapeutic targets in human cancer.

Authors:  Ylenia Cicirò; Arturo Sala
Journal:  Oncogenesis       Date:  2021-02-26       Impact factor: 7.485

Review 6.  The ST2/Interleukin-33 Axis in Hematologic Malignancies: The IL-33 Paradox.

Authors:  Alessandro Allegra; Vanessa Innao; Gennaro Tartarisco; Giovanni Pioggia; Marco Casciaro; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-10-22       Impact factor: 5.923

7.  Next-generation sequencing in two cases of de novo acute basophilic leukaemia.

Authors:  Takuya Shimizu; Tadakazu Kondo; Yasuhito Nannya; Mizuki Watanabe; Toshio Kitawaki; Takero Shindo; Masakatsu Hishizawa; Kouhei Yamashita; Seishi Ogawa; Akifumi Takaori-Kondo
Journal:  J Cell Mol Med       Date:  2021-06-16       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.